Takeda Pharmaceutical Company the largest pharmaceutical company in Japan and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that the FDA has approved an extended release version of the combination medication ACTOplus met(R) and metformin HCl for the treatment of type 2 diabetes in addition to diet and exercise . ACTOplus met(R) XR is the first and only prescription oral anti-diabetic fixed-dose combination medication available with the extended release form of Metformin. This will be available in a convenient, once-daily dosing option. ACTOplus met XR is intended to be used by adults with type 2 diabetes.
ACTOplus met XR combines ACTOS and metformin, two widely used medications in a single tablet. ACTOS directly targets insulin resistance, a condition in which the body does not efficiently use the insulin it produces. Metformin acts by reducing the amount of glucose produced by the liver. Combined, these two medications work in combination to help patients with type 2 diabetes manage their blood sugar levels. Takeda expects ACTOplus met XR to be available later this calendar year.
Diabetes has reached epidemic proportions in the United States. Almost 24 million people currently live with diabetes and it is estimated that roughly 5.7 million more Americans are unaware that they even have it. Type 2 diabetes is a progressive and chronic condition and requires continued monitoring by a patient and their physician. In addition to diet and exercise, patients may need to take multiple medications to help maintain glucose control. In 2007, the world is estimated to have spent at least $232 billion to treat and prevent diabetes and its complications. By 2025, this estimate will exceed $302.5 billion. For Americans that do not have insurance coverage and meet certain income guidelines there is prescription drug help available through various assistance programs. Check with the individual drug company or contact Rx HELP to see if you might qualify.